quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:10:03·116d
ANALYSTRating
Amicus Therapeutics Inc. logo

Amicus Therapeutics downgraded by Leerink Partners with a new price target

FOLD· Amicus Therapeutics Inc.
Health Care
Original source

Companies

  • FOLD
    Amicus Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 22UpdateJefferies$14.50
  • Dec 29UpdateLeerink Partners$14.50
  • Dec 22UpdateTD Cowen$14.50
  • Dec 17UpdateCitigroup$17.00
  • Sep 18UpdateNeedham$14.00
  • Jul 17UpdateMorgan Stanley$108.00

Related

  • SEC16h
    SEC Form 8-K filed by Amicus Therapeutics Inc.
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.
  • INSIDER50d
    President and CEO Campbell Bradley L sold $322,839 worth of shares (22,500 units at $14.35), decreasing direct ownership by 2% to 998,680 units (SEC Form 4)
  • SEC51d
    Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
  • SEC59d
    SEC Form DEFA14A filed by Amicus Therapeutics Inc.
  • SEC62d
    SEC Form 10-K filed by Amicus Therapeutics Inc.
  • SEC62d
    Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR62d
    Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022